Elicio Therapeutics (ELTX) Net Cash Flow Growth (1y) (2021 - 2026)
Elicio Therapeutics (ELTX) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-14,223.53% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Elicio Therapeutics |
70.12 Mn |
55.17 Mn |
- |
-1,831.10% |
| Date | Value |
| Mar 31, 2026 |
-1,831.10% |
| Dec 31, 2025 |
77.22% |
| Sep 30, 2025 |
-106.45% |
| Jun 30, 2025 |
134.46% |
| Mar 31, 2025 |
119.09% |
| Dec 31, 2024 |
-195.85% |
| Sep 30, 2024 |
554.16% |
| Jun 30, 2024 |
-171.72% |
| Mar 31, 2024 |
-158.12% |
| Dec 31, 2023 |
-176.06% |
| Sep 30, 2023 |
-252.37% |
| Jun 30, 2023 |
76.47% |
| Mar 31, 2023 |
112.03% |
| Dec 31, 2022 |
127.19% |
| Sep 30, 2022 |
123.30% |
| Jun 30, 2022 |
152.00% |
| Mar 31, 2022 |
-116.34% |
| Dec 31, 2021 |
-167.33% |
| Sep 30, 2021 |
-257.01% |
| Jun 30, 2021 |
-410.17% |